The merger, the terms of which were not disclosed, is expected to expand on Becton’s healthcare worker safety technologies for prefilled syringe customers, according to the company.
"We believe the Safety Syringes product line is a valuable asset to BD and aligns well with our focus on healthcare worker safety, and offering higher-value products," president of BD’s Medical Pharmaceutical system Claude Dartiguelongue said in prepared remarks. "We are excited about this acquisition, which expands the company’s presence in safety technologies and further demonstrates BD’s commitment to developing innovative solutions that help address our customers’ unmet needs."
Becton in July signed a definitive agreement to acquire Safety Syringes, aiming to boost its passive safety offerings with Safety Syringes’ needle shields and guards, which are currently offered for prefilled syringes with more than 20 drugs.
The company expects the transaction to be minimally dilutive for fiscal 2012 without impacting previous guidance.
Earlier this year BD raised its full-year sales guidance from flat to between 1% and 2% and boosted its diluted EPS forecast from $5.60-$5.70 to $5.68-$5.73. The company also said it plans to repurchase $1.5 billion worth of its own stock during 2012.